Loading clinical trials...
Loading clinical trials...
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
NCT07665931 · Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Hyperinflation
NCT07646587 · COPD (Chronic Obstructive Pulmonary Disease)
NCT05743582 · Chronic Obstructive Pulmonary Disease
NCT07190222 · Chronic Obstructive Pulmonary Disease
NCT07047092 · Chronic Obstructive Pulmonary Disease Exacerbation, Obstructive Sleep Apnea Exacerbation
Spartanburg Medical Research
Spartanburg, South Carolina
Harrison Clinical Research Deutschland GmbH
Albrechtstrasse 14, Munich
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions